

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	OSPREY MEDICAL INC.
ABN	ARBN 152 854 923

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	John Erb
Date of last notice	26 May 2015

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct														
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Issue of Options to John Erb with an exercise price of A\$0.82 per share of common stock (Share) and an expiry date of 26 August 2020 (following stockholder approval on 18 May 2017)														
Date of change	19 May 2017 (AEST)														
No. of securities held prior to change	<table><tr><td>20,000</td><td>Options with exercise price of US\$0.50 per Share</td></tr><tr><td>5,000</td><td>Options with exercise price of US\$0.50 per Share</td></tr><tr><td>73,839</td><td>Options with exercise price of US\$0.25 per Share</td></tr><tr><td>190,000</td><td>Options with exercise price of US\$0.80 per Share</td></tr><tr><td>100,000</td><td>Options with exercise price of A\$1.31 per Share</td></tr><tr><td>60,000</td><td>Options with exercise price of A\$1.16 per Share</td></tr><tr><td>Total:</td><td>448,839 Options (exercisable into an equivalent of 897,678 CHESS Depositary Interests (CDIs))</td></tr></table>	20,000	Options with exercise price of US\$0.50 per Share	5,000	Options with exercise price of US\$0.50 per Share	73,839	Options with exercise price of US\$0.25 per Share	190,000	Options with exercise price of US\$0.80 per Share	100,000	Options with exercise price of A\$1.31 per Share	60,000	Options with exercise price of A\$1.16 per Share	Total:	448,839 Options (exercisable into an equivalent of 897,678 CHESS Depositary Interests (CDIs))
20,000	Options with exercise price of US\$0.50 per Share														
5,000	Options with exercise price of US\$0.50 per Share														
73,839	Options with exercise price of US\$0.25 per Share														
190,000	Options with exercise price of US\$0.80 per Share														
100,000	Options with exercise price of A\$1.31 per Share														
60,000	Options with exercise price of A\$1.16 per Share														
Total:	448,839 Options (exercisable into an equivalent of 897,678 CHESS Depositary Interests (CDIs))														

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Class	Options over Shares (not quoted)
Number acquired	110,000 Options (exercisable into an equivalent of 220,000 CDIs)
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	<p>20,000 Options with exercise price of US\$0.50 per Share</p> <p>5,000 Options with exercise price of US\$0.50 per Share</p> <p>73,839 Options with exercise price of US\$0.25 per Share</p> <p>190,000 Options with exercise price of US\$0.80 per Share</p> <p>100,000 Options with exercise price of A\$1.31 per Share</p> <p>60,000 Options with exercise price of A\$1.16 per Share</p> <p>110,000* Options with exercise price of A\$0.82 per Share</p> <p>Total: <u>558,839</u> Options (exercisable into an equivalent of 1,117,678 CDIs)</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	*Issue of Options to John Erb was in accordance with the Osprey Medical 2016 Stock Incentive Plan. The grant of Options was approved by stockholders on 18 May 2017 as part of the company's Annual Stockholder meeting.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A

+ See chapter 19 for defined terms.

No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.